Long-term study of ACP-204 for psychosis linked to Alzheimer's disease
Checks the long-term safety of ACP-204 in older adults with Alzheimer's psychosis.
Plain-language title generated from the registry record
Registry title: ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Key facts
- Where
- Cherven Bryag, Kirdzhali, Pazardzhik, Pleven, Plovdiv, Sofia, Sofiya, and Stara Zagora, BulgariaSee the 12 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 95 years old?
Source: NCT06194799, who can take part
Where in Bulgaria
- Dr. Ivo Natsov Outpatient Clinic For Individual Practice For Specialized Medical Care In Psychiatry ETCherven Bryag, BulgariaTaking people
- Medical Center Lifemed EOODKirdzhali, BulgariaTaking people
- Higya–DCC OODPazardzhik, BulgariaTaking people
- Medical Center Medconsult Pleven OODPleven, BulgariaTaking people
- Medical Center Spectar Plovdiv EOODPlovdiv, BulgariaTaking people
- University Multiprofile Hospital For Active Treatment Saint Georgi EADPlovdiv, BulgariaTaking people
- Alexandrovska University HospitalSofia, BulgariaTaking people
- Center For Mental Health Prof. N. Shipkovenski EOODSofia, BulgariaTaking people
- Diagnostic And Consultation Centre St.Vrach And St.St. Kuzma And Damian OODSofiya, BulgariaTaking people
- Medical Center Hera EOODSofiya, BulgariaTaking people
- Medical Center Intermedica Ltd.Sofiya, BulgariaTaking people
- Umbal - Prof. D-R Stoyan Kirkovich ADStara Zagora, BulgariaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ACADIA Pharmaceuticals Inc.
- Trial code
- NCT06194799EU 2023-507351-29-00
- Record updated
- 4 November 2026
- Original description
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.Read full original descriptionShow less
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Inclusion: Subject has successfully completed ACP-204-006 study; Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential; Subject has a designated study partner/caregiver; Subjects are able to complete all study visits with a study partner/caregiver; Signed inform consent form with a caregiver or legal representative.
Exclusion: Requires treatment with a medication prohibited by the protocol; Is in hospice and receiving end-of-life palliative care, or has become bedridden; Unstable clinically significant medical condition other than AD; Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study; Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.